Recall of Sandoz Apixaban 2.5mg and 5mg Tablets Due to Outdated Leaflet

Source: MHRA · United Kingdom

Areazine synthesizes this MHRA medicine alert directly from MHRA's official public data feed. See our methodology for full source attribution and refresh cadence.

Sandoz Limited has notified the MHRA of a recall for certain batches of Apixaban 2.5mg and 5mg tablets because the patient information leaflet contains outdated information.

What this MHRA medicine alert tells you, and what most readers miss

This notice was issued by MHRA on March 26, 2026 and geographically references United Kingdom. Its severity classification of "low" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Medicine Alerts - determines the consumer-protection framework behind it, which shapes what remedies (refunds, replacements, repairs, or the recall itself) are available to affected consumers and which agency holds statutory responsibility for enforcement.

Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly MHRA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action, a single localized MHRA medicine alert is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.

For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (recall, product-safety, MHRA, medicine) map to related alerts in the same area of risk - browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.

Recall Article

What Happened

The Patient Information Leaflet included in specified batches of Apixaban tablets does not contain up-to-date information, as notified by Sandoz Limited to the MHRA.

Which Products Are Affected

The affected products are Apixaban 2.5mg and 5mg Tablets manufactured by Sandoz Limited. No specific model numbers, UPCs, quantities, or date ranges were provided in the notification.

What You Should Do

Consumers should refer to the official MHRA alert for information on the affected batches and any recommended actions.

Why This Matters

This recall addresses a defect in product information to ensure accurate usage, but it is classified as low severity with minimal safety impact.

Source

MHRA alert: Class 4 Medicines Defect Notification

Original source: MHRA Official Notice ↗

All Medicine Alerts →

Frequently Asked Questions

Common questions about this MHRA medicine alert.

What is this MHRA medicine alert about?
Sandoz Limited has notified the MHRA of a recall for certain batches of Apixaban 2.5mg and 5mg tablets because the patient information leaflet contains outdated information.
Which agency issued this alert?
This alert was issued by MHRA. The original notice is available at the source link at the bottom of this article.
How severe is this alert?
This alert is classified as "low" severity. No immediate action required, but stay aware.
What area is affected?
This alert affects United Kingdom. Check with MHRA for the most current geographic scope.
Where can I find more Medicine Alerts updates?
Browse the full Medicine Alerts feed on Areazine at areazine.com/uk/recalls/medicine/ for the latest updates from MHRA and other agencies.